11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
7 citations
,
October 2022 in “Expert opinion on emerging drugs” New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
7 citations
,
December 2020 in “Clinics in Dermatology” Some alopecia treatments might help treat COVID-19, but more research is needed.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
4 citations
,
November 2015 in “Hanbang an'i'bi'in'hu pibu'gwa haghoeji” Finasteride, Dutasteride, and Minoxidil are effective for hair growth, while new treatments like laser therapy and PRP show promise with few side effects.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
2 citations
,
August 2023 in “Journal of the American Academy of Dermatology” New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
1 citations
,
August 2024 in “JAAD Case Reports” Tick bites can cause hair loss similar to alopecia areata, and baricitinib may help regrow hair.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.